Calypte Biomed, hab heute wieder mal gekauft !

und dann ................. weiß doch auch nicht was kommt, ätsch.

einfach abwarten und einen wunderschönen Montag wünsch ich allen, grins :-P

gruß werweiß  

 

Erst morgen wissen wir, was der Tag heute gebracht hat. Darum heute alle schön die Ruhe behalten.

Grüße, ZN  

 

wenn nicht 15,30 dann etwas später.
Denn die Insider sind gewappnet, denn die werden erst beim Anstieg kaufen und in kleineren shares wegen der SEC etc.
Auf allen anderen Foren in US sind Sie davon überzeugt, sogar das Magic heute etwas daszu sagt, und zwar in seiner eigenen Klinik.
In Insiderkreisen spricht man sogar das den fertigen Urintest bekannt gibt. Woran noch viele zweifeln das es Ihn gibt !  

Nase,ich halt nichts vom "daytrade", auch nicht vom "rein und raus". Meine Aussage soll nicht als solches missverstanden werden. Außerdem kann ich mich auch irren, den die Umsätze waren nicht gerade sehr hoch am Freitag, auch wenn der Handel kürzer war als sonst. Ich glaube aber, wenn alle auf eine Meldung vorher spekulieren, kommen mit der Meldung, auch meist auch die Gewinnmitnahmen. Egal was kurzfristig  mit der Aktie passiert, längerfristig bin ich nach wie vor positiv.

Doncamiloo: Welche Insiderkreisen kreise meinste denne??  

 

Magig hat was gesagt, sagen die RainingBulls:

http://ragingbull.lycos.com/mboard/boards.cgi?board=CYPT

hat er nun nur "Urintest", oder "die Urintest von Calypte", oder was auch immer gesagt.
Macht Euch selber ein Bild!  

CYPT says minimal revenues from international sales in the 4th quarter of this year. The TESTS ARE NOT SELLING OVERSEAS, DESPITE ALL THE HYPE!!!

Guidance

We projected third quarter 2003 revenues to be in the range of $900,000 to $1,000,000. Revenue for the third quarter was $897,000. Although we are adding new customers, achieving regulatory approvals and making in-roads on what we believe to be significant international contracts, our experience indicates that the approval, selling and delivery cycle generally takes six months or more before we recognize incremental revenue from those additions. We are currently projecting fourth quarter 2003 revenues to be approximately equal to those of the third quarter, or approximately $900,000 to $1,000,000. Domestically, we anticipate a modest increase in sales to LabOne as a result of the recently negotiated multi-year contract for their purchase of our urine-based HIV tests for use in the life insurance industry. Internationally, we have achieved certain approvals for our current urine-based screening tests that we believe will facilitate the acceptance of our urine rapid products in 2004, however we anticipate minimal revenues from international sales of our current products in the fourth quarter of 2003.

from the current 10Q SEC filing...  

Alle die jenigen die mehr oder weniger im Publikum der Veranstaltungen
sitzen.
Oder als Fan`s Magic begleiten.
Denn wir sind hier viel zuweit weg vom Geschehen.  

Quelle ebenfalls RainingBull:
" I listened to the entire interview with Katie Courik. Magic Johnson stated very clearly on the Today show at 8:45AM EST that Calypte has the rapid test. "  

2-Millionen-Dollar-Auftrag für HIV-Schnelltests(20 Minuten).

CDC Commits Additional $2 Million for Purchase of
OraQuick Rapid HIV-1 Antibody Tests
Monday December 1, 6:00 am ET

BETHLEHEM, Pa.--(BUSINESS WIRE)--Dec. 1, 2003--OraSure Technologies, Inc. (Nasdaq
NM:OSUR - News), the market leader in oral fluid diagnostics, announced today that The
Centers for Disease Control and Prevention ("CDC") has committed to purchase an additional
250,000 OraQuick® Rapid HIV-1 Antibody Tests for a total of $2 million. The CDC purchase is
expected to be fulfilled by September 1, 2004, and further supports its four-part HIV prevention
strategy, which was previously announced on April 17, 2003.

This is the second bulk purchase of OraQuick® tests made by the CDC and is clearly
indicative of the early success of this initiative. The first purchase of 250,000 tests for $2 million
was announced on June 26, 2003.

Today's announcement was made by OraSure's President and Chief Executive Officer, Mike
Gausling, who presided over the NASDAQ Stock Market Open today in recognition of World
AIDS Day. The market open ceremony can be viewed online at
http://www.nasdaq.com/reference/marketsite_about.stm.

"We are extremely grateful for the CDC's continuing support of rapid testing and are pleased to
announce this additional procurement of OraQuick® on World AIDS Day," said Mike Gausling,
President and Chief Executive Officer of OraSure Technologies. "With this purchase, the
Administration has again demonstrated its leadership in promoting rapid HIV testing as an
important component in its comprehensive HIV prevention strategy. I would especially like to
thank U.S. Senators Arlen Specter and Rick Santorum for their support of OraSure and
commitment to combating the global AIDS crisis."

"It is particularly important to recognize the need for increased vigilance against the spread of
HIV, and to reaffirm the Administration's commitment to fighting the virus through all possible
means," said Senator Arlen Specter. "OraSure's development of the OraQuick® test is a giant
step in combating the global AIDS crisis. With this test, people will be able to more easily and
efficiently screen for HIV, which will help prevent those infected from passing the virus to others
and allow them to more effectively treat their disease."

"Clearly, one of the keys to addressing the significant public health problems that the spread of
HIV/AIDS poses for our country and the rest of the world is first identification of infected
populations, and then ongoing treatment," said Senator Rick Santorum. "OraSure's
ground-breaking rapid HIV test can play an important role in complementing our public health
strategies for research, prevention initiatives and efforts to expand access to quality health care
and services for those who need them."

OraQuick® is a rapid, point-of-care test designed to detect antibodies to HIV-1 within 20
minutes. OraSure has FDA approval of the OraQuick® device to test finger-stick and
venipuncture whole blood specimens for antibodies to HIV-1. In addition, OraSure has received
a CLIA (Clinical Laboratory Improvement Amendments of 1988) waiver for this test, thereby
permitting the test to be used in more than 180,000 sites in the United States, such as
outreach clinics, community-based organizations and physicians' offices.

Please Note: "Live" coverage of the NASDAQ Stock Market opening ceremony on Monday,
December 1, from 9:20 a.m. to 9:35 a.m. EDT is available via satellite on Galaxy
4R/Transponder 20. The downlink frequency is 4100 vertical; audio: 6.2/6.8. The feed can also
be found on Waterfront fiber 1623. In addition, World AIDS Day interview footage and b-roll of
the OraQuick® test will be available via satellite on Monday, December 1 at 2 p.m. EDT via
satellite on Telstar 4C/Transponder 10, D/L Frequency: 3900 (V).

In addition, World AIDS Day interview footage and b-roll of the OraQuick® test will be available
via satellite on Monday, December 1 at 2:00 p.m. - 2:15 p.m. EST via satellite on the following
coordinates:

Ku Band - Analog (in the clear)
SBS 6, Transponder 19 Upper
Downlink Frequency: 12178
Downlink Polarity: Horizontal
Audio: 6.2 and 6.8

About OraSure Technologies

OraSure Technologies develops, manufactures and markets oral fluid specimen collection
devices using proprietary oral fluid technologies, diagnostic products including immunoassays
and other in vitro diagnostic tests, and other medical devices. These products are sold in the
United States as well as internationally to various clinical laboratories, hospitals, clinics,
community-based organizations and other public health organizations, distributors, government
agencies, physicians' offices, and commercial and industrial entities.

OraSure Technologies is the leading supplier of oral-fluid collection devices and assays to the
life insurance industry and public health markets for the detection of antibodies to HIV-1. In
addition, the Company supplies oral-fluid testing solutions for drugs of abuse testing. For more
information on the Company, please go to www.orasure.com.



 

setzt schon 2 Mio $ um und Caly noch so gut wie nix. Sieht so aus, als würde Caly hinterher rennen auch wenn beide Testverfahren total unterschiedlich sind. Bin mal gespannt, wie die Börse das alles so aufnimmt.


Grüße, ZN  

ist ganz schön teuer. Die von Caly kosten 2 USD!

Doncamiloo, es ist einer der älteste Trugschlusse an der Börse, zu glauben die anderen seien besser informiert. Mit Deinem Internetanschluss bist Du so nahe dran wie alle anderen.    
 

Außerdem scheint die Firma gute Connects in die Politik zu haben - siehe die Danksagung an die zwei Herren Senatoren :-)



 

Schön für ORASURE, der Laden ist trotzdem total überbewertet. Ich werd mal ein Paar Papiere Short verkaufen und dann Our-Street was suchen lassen.  

wie es scheint habe ich mich geirrt. Da schlage ich mich schon mal auf Deine Seite und dann das:

bid ask up. .775/.78 schwab. EOM
77.5 x 78 right now on Level II - 9:20am EST

Naja, Pessimismus muss bestraft werden. Asche auf mein Haupt!
 

 

du hast ja wohl nicht etwa verkauft?
Grüße, ZN  

scheint so: Open: ,77 USD würde ich mal sagen.  

neee bin noch mit 50.000 dabei! Bin mit 40K bis Juni nächstes Jahr gebunden.  

 

 

.785 X .785 at Fidelity (eom).
 

Ich habe 12000 und habe weiche Knie !